<DOC>
	<DOCNO>NCT01357655</DOCNO>
	<brief_summary>The purpose study compare response rate newly diagnose Chronic Phase ( CP ) CML subject treat dasatinib plus BMS-833923 versus dasatinib alone .</brief_summary>
	<brief_title>Phase 2 Dasatinib Combo With Smoothened ( SMO ) Antagonist ( BMS-833923 )</brief_title>
	<detailed_description>1 . Design : Study Design Duration current describe longer applicable since enrollment prematurely conclude due decision sponsor . Subjects currently enrol trial continue receive dasatinib alone start dose 100 mg QD : 1. maximum 5 year entry study 2. progression Investigators determination/judgment 3. intolerance Dasatinib 4. study terminate due safety concern 5. administrative reason communicate sponsor 2 . Research Hypothesis : The research hypothesis primary objective study originally design longer applicable subject enrolment terminate due administrative reason sponsor . The objective altered design study describe safety profile tolerability dasatinib</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Subjects â‰¥ 18 year age sign informed consent Philadelphia positive Chronic Myeloid Leukemia ( CML ) chronic phase Previously untreated chronic phase CML , except Anagrelide Hydroxyurea . Eastern CoOperative Group ( ECOG ) Performance Status ( PS ) Score 0 2 Known Ablkinase T315I T315A mutation Serious uncontrolled medical disorder ( include infection cardiovascular disease ) dementia serious psychiatric condition Prior chemotherapy . Women pregnant breastfeed Women Child Bearing Potential ( WOCBP ) unwilling unable use acceptable method avoid pregnancy entire study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Myelogenous</keyword>
	<keyword>Chronic</keyword>
	<keyword>BCR-ABL Positive</keyword>
</DOC>